Adaptimmune Therapeutics PLC — Director's Dealing 2016

Jan 4, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2016-01-01

Reporting Person: Tayton-Martin Helena Katrina (Chief Operating Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares with a nominal value of GBP0.001 per share	1815000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to purchase Ordinary Shares	$0.1671	2022-01-25	Ordinary Shares (192500)		Direct
Option to purchase Ordinary Shares	$0.1671	2023-01-01	Ordinary Shares (742500)		Direct
Option to purchase Ordinary Shares	$0.1671	2024-04-14	Ordinary Shares (850000)		Direct
Option to purchase Ordinary Shares	$0.5308	2024-12-19	Ordinary Shares (1750000)		Direct

Footnotes

F1: Currently exercisable as to 144,300 Ordinary Shares and will be exercisable as to 48,200 Ordinary Shares on January 25, 2016.

F2: Currently exercisable as to 694,500 Ordinary Shares and will be exercisable as to 48,000 Ordinary Shares on January 1, 2017.

F3: Currently exercisable as to 212,500 Ordinary Shares and will be exercisable as to the remainder ratably in annual installments on the fourteenth of April from April 14, 2016 through April 14, 2018.

F4: Exercisable as to 437,500 Ordinary Shares on December 19, 2015 and will be exercisable as to the remainder in monthly installments of 36,400 Ordinary Shares on the nineteenth of each month from January 19, 2016 through November 19, 2018, and in one installment of 38,500 Ordinary Shares on December 19, 2018.

F5: The exercise price was converted from GBP0.112 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

F6: The exercise price was converted from GBP0.112 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

F7: The exercise price was converted from GBP0.112 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.

F8: The exercise price was converted from GBP0.3557 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.